The internal DISA program is based on the TREX1 inhibition pathway, which potentially supports the effect of immuno-oncology therapy, radiation therapy, and chemotherapy in the treatment of cancer. Our take is that Sprint Bioscience is increasingly well-placed to attract a DISA TREX1 inhibitor program partner.